Modulation of NAD+ metabolic pathways for treatment of disease
The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.
1. A method of modulating a kynurenine to tryptophan ratio in a subject in need thereof, the method comprising administering a composition comprising a nicotinamide adenine dinucleotide (NAD+) precursor to the subject,
wherein the composition comprising the NAD+ precursor modulates the kynurenine to tryptophan ratio in the subject;
wherein the NAD+ precursor is administered in combination with an indoleamine 2,3-dioxygenase (IDO) antagonist.
2. The method of claim 1 , wherein the NAD+ precursor is a nicotinamide riboside.
3. The method of claim 1 , wherein the subject has a disease selected from the group consisting of a disease having an immunosuppressive character, viral infections, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, bacterial infections, parasitic infections, comorbidities of viral infections, cancers, neurodegenerative diseases or disorders, immune-mediated disorders, inflammatory diseases, cardiovascular diseases, kidney diseases, autoimmune diseases, lupus, systemic lupus erythematosus, age-related disorders, diabetes, obesity, insulin resistance, eating disorders, metabolic syndrome, pain, migraine, rheumatoid arthritis, osteoporosis, sleep disorders, mood disorders, psychiatric diseases or disorders, neurologic diseases or disorders, depression, schizophrenia, Alzheimer disease and Parkinson's Disease.
4. A method of treating a disease in a subject, the method comprising modulating the kynurenine to tryptophan ratio in the subject,
wherein the method comprises administering a composition comprising a NAD+ precursor to the subject;
wherein the composition comprising the NAD+ precursor modulates the kynurenine to tryptophan ratio in the subject;
wherein the NAD+ precursor is administered in combination with an indoleamine 2,3 dioxygenase (IDO) antagonist; and
wherein the disease is selected from the group consisting of a disease having an immunosuppressive character, viral infections, human immunodeficiency virus (HIV) infection, and comorbidities of viral infections.